3D Bioprinted Cardiac Patches are engineered heart tissues created layer-by-layer using bioprinting technology, designed to repair damaged myocardial tissue after a heart attack. These patches typically consist of patient-derived induced pluripotent stem cell-derived cardiomyocytes, fibroblasts, and endothelial cells embedded in a biocompatible hydrogel bioink. Major research efforts are underway at institutions like the University of Toronto, Tel Aviv University, and the Texas Heart Institute, with companies like BioLife Solutions also involved in related bio-processing. The technology is currently in advanced research and preclinical testing stages, demonstrating integration and improved heart function in animal models. In January 2023, a team at Tel Aviv University successfully bioprinted a vascularized cardiac patch that integrated into a rat heart and improved cardiac function post-infarction, published in *Advanced Functional Materials*. This aims to replace conventional scar tissue formation after a heart attack, which impairs function and often leads to heart failure.
Editorial check
How this page is checked
Source trail
feinberglab.com
External links are separated from Surfaced commentary.
Reader safety
Context before clicks
Product links and external services are not presented as guarantees.
Monetization
No affiliate flag
Ads and commerce links are kept distinct from editorial text.
Surfaced take
Why It Matters
Heart failure affects over 6.2 million adults in the US, with myocardial infarction being a leading cause, resulting in irreversible heart tissue damage and high mortality rates. Bioprinted cardiac patches could regenerate damaged heart muscle, preventing the progression to heart failure and significantly improving patient quality of life and longevity. Patients with heart disease and cardiologists win; manufacturers of pacemakers or ventricular assist devices might see shifts in demand. Technical challenges include ensuring long-term graft survival, mechanical integration with existing heart tissue, and achieving synchronized electrical activity with the host heart. Regulatory approval for such a critical implant will also be a hurdle. Human clinical trials are projected within 5-8 years, with widespread availability in 15-20 years. Research teams in North America (e.g., Canada, US) and Israel are particularly competitive in this domain. A second-order consequence could be the ethical questions surrounding the 'perfection' of human organs and the potential for elective cardiac enhancement in the future.
Development Stage
Related
Scrintal
Scrintal is a visual knowledge canvas and note-taking tool developed by a startup, designed to help users think spatially and connect ideas on an infinite…
Jasper
Jasper is an AI content platform developed by Jasper AI, designed to help individuals and teams generate high-quality written content quickly and efficiently…
Enjoyed this? Get five picks like this every morning.
Free daily newsletter — zero spam, unsubscribe anytime.